A phase I study of oral uracil/ftorafur (UFT) plus leukovorin in combination with weekly paclitaxel (P) in patients (pts) with solid tumors.

被引：0
|
作者：
Mayer, F
von Pawel, J
Beck, J
Schroeder, M
Hartmann, JT
Kanz, L
Bokemeyer, C
机构：
[1] St Johannes Hosp, Duisburg, Germany
[2] Univ Mainz, D-6500 Mainz, Germany
[3] Asklepios Fachklin Munchen Gauling, Munich, Germany
[4] Univ Tubingen, Med Ctr, Dept Hematol Oncol, Tubingen, Germany
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
620P
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [1] A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors
    Mayer, F
    Hartmann, JT
    von Pawel, J
    Beck, J
    Schroeder, M
    Boehlke, I
    Kanz, L
    Bokemeyer, C
    ANNALS OF ONCOLOGY, 2002, 13 (05) : 755 - 759
  • [2] Phase I study of paclitaxel, UFT and leucovorin calcium in patients with metastatic solid tumors.
    Tkaczuk, KH
    Doyle, LA
    Tait, N
    Quinn, C
    Duckham, E
    Buadi, F
    Chen, T
    Edelman, M
    ANNALS OF ONCOLOGY, 2000, 11 : 137 - 137
  • [3] Results of a phase Ib study of ARQ 092 in combination with carboplatin (C) plus paclitaxel (P), or with P in patients (pts) with solid tumors.
    Lakhani, Nehal
    Tolcher, Anthony W.
    Rasco, Drew W.
    Patnaik, Amita
    O'Rourke, Timothy J.
    Schwartz, Brian E.
    Abbadessa, Giovanni
    Kazakin, Julia
    Savage, Ronald
    Wang, Yunxia
    Chai, Feng
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.
    Gao, Fangfei
    O'Brien, Mary
    Sarker, Debashis
    Bhosle, Jaishree
    Yap, Timothy Anthony
    Uttenreuther-Fischer, Martina Maria
    Pemberton, Karine
    Goeldner, Rainer-Georg
    Wiebe, Sabrina
    De Bono, Johann S.
    Spicer, James F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs)
    Heath, E. I.
    Blumenschein, G. R., Jr.
    Cohen, R. B.
    LoRusso, P. M.
    LoConte, N. K.
    Kim, S. T.
    Chao, R.
    Wilding, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors.
    Chiorean, E. G.
    Matei, D.
    Younger, A.
    Funke, J. M.
    Waddell, M. J.
    Jones, D. R.
    Hahn, N. M.
    Perkins, S. M.
    Sandrasegaran, K.
    Sweeney, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A phase I clinical and pharmacokinetic (PK) study of paclitaxel (P) and docetaxel (D) in patients (PTS) with solid tumors.
    Izquierdo, MA
    Pontón, JL
    García, M
    Navarro, M
    Mesia, R
    Cardenal, F
    Gil, M
    Germá, JR
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S84 - S84
  • [8] Phase I clinical trial of pulse dose imatinib (Im) and weekly paclitaxel (P) in patients (pts) with advanced refractory solid tumors.
    Firozvi, KA
    Moore, D
    Min, FD
    Malik, S
    Egorin, M
    Hwang, JJ
    Ramzi, P
    Marshall, JL
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9117S - 9118S
  • [9] Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors
    Tan, Antoinette R.
    Dowlati, Afshin
    Jones, Suzanne F.
    Infante, Jeffrey R.
    Nishioka, Jennifer
    Fang, Lei
    Hodge, Jeffrey P.
    Gainer, Shelby D.
    Arumugham, Thangam
    Suttle, A. Benjamin
    Dar, Mohammed M.
    Lager, Joanne J.
    Burris, Howard A., III
    ONCOLOGIST, 2010, 15 (12): : 1253 - 1261
  • [10] A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
    Chan, Nancy
    Portal, Daniella E.
    Moss, Rebecca Anne
    Silk, Ann W.
    Stein, Mark N.
    Aisner, Joseph
    Malhotra, Jyoti
    Shih, Weichung
    Lin, Hongxia
    Kane, Michael P.
    Mehnert, Janice M.
    Tan, Antoinette R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345